Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?

The role of allogeneic hematopoietic cell transplant (HCT) in the treatment of older patients with hematologic malignancies has rapidly evolved over the past 2 decades. Historically, older patients were not offered HCT despite being both disproportionally affected by hematologic malignancies and having a higher propensity for higher risk/more aggressive disease. In fact, it was estimated as recently as 2011 that only 6% of patients with acute myelogenous leukemia (AML) older than 60 years in the United States underwent stem cell transplantation [1].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: Commentary Source Type: research